Movatterモバイル変換

[0]ホーム
URL:

Wayback Machine
17 captures
11 Apr 2016 - 01 Jun 2024
FebMARApr
27
201820192020
success
fail
COLLECTED BY
TIMESTAMPS
loading
The Wayback Machine - https://web.archive.org/web/20190327183410/https://ajp.psychiatryonline.org/toc/ajp/162/5

Change Password

Too ShortWeakMediumStrongVery StrongToo Long

Password Changed Successfully

Your password has been changed

Create your account

Forget yout Password?

Enter your email address below and we will send you the reset instructions

If the address matches an existing account you will receive an email with instructions to reset your password

Forgot your Username?

Enter your email address below and we will send you your username

If the address matches an existing account you will receive an email with instructions to retrieve your username

Psychiatry Online
Sections

The American Psychiatric Association (APA) has updated itsPrivacy Policy andTerms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
cover

American Journal of Psychiatry

Volume 162, Issue 5

May 2005
In This Issue
Editorial
Reviews and Overviews
May 2005
The Case for Practical Clinical Trials in Psychiatry
  • Pages:836–846
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.836

Preview Abstract
OBJECTIVE: Clinical trials in psychiatry frequently fail to maximize clinical utility for practicing clinicians, or, stated differently, available evidence is not perceived by clinicians (and other decision makers) as sufficiently relevant to clinical ...
May 2005
Somatoform Disorders: Time for a New Approach in DSM-V
  • Pages:847–855
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.847

Preview Abstract
OBJECTIVE: DSM-III introduced somatoform disorders as a speculative diagnostic category for somatic symptoms “not explained by a general medical condition.” Although retained and enlarged in DSM-IV, somatoform disorders have been the subject of continuing ...
Images in Neuroscience
Introspections
Clinical Case Conference
Images in Psychiatry
Article
May 2005
Borderline Personality Disorder in Clinical Practice
  • Pages:867–875
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.867

Preview Abstract
OBJECTIVE: Most studies of borderline personality disorder have drawn patients from among hospital inpatients or outpatients. The aims of this study were to examine the nature of borderline personality disorder patients in everyday clinical practice and ...
May 2005
The Changing Prevalence and Severity of Obsessive-Compulsive Disorder Criteria From DSM-III to DSM-IV
  • Pages:876–882
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.876

Preview Abstract
OBJECTIVE: Relative to other mental disorders, the prevalence of obsessive-compulsive disorder (OCD) in the general population is not well established. Some epidemiological surveys have determined the prevalence of DSM-III OCD, but this is one of the ...
May 2005
Two-Year Prevalence and Stability of Individual DSM-IV Criteria for Schizotypal, Borderline, Avoidant, and Obsessive-Compulsive Personality Disorders: Toward a Hybrid Model of Axis II Disorders
  • Pages:883–889
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.883

Preview Abstract
OBJECTIVE: This study tracked the individual criteria of four DSM-IV personality disorders—borderline, schizotypal, avoidant, and obsessive-compulsive personality disorders—and how they change over 2 years. METHOD: This clinical sample of patients with ...
May 2005
Countertransference Phenomena and Personality Pathology in Clinical Practice: An Empirical Investigation
  • Pages:890–898
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.890

Preview Abstract
OBJECTIVE: This study provides initial data on the reliability and factor structure of a measure of countertransference processes in clinical practice and examines the relation between these processes and patients’ personality pathology. METHOD: A ...
May 2005
Dissociation, Childhood Interpersonal Trauma, and Family Functioning in Patients With Somatization Disorder
  • Pages:899–905
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.899

Preview Abstract
OBJECTIVE: The goals of this study were to determine 1) the occurrence of various dissociative phenomena in patients with somatization disorder, 2) the occurrence of six different types of childhood interpersonal trauma in these patients, and 3) the ...
May 2005
Temperament and Character Profiles and the Dopamine D4 Receptor Gene in ADHD
  • Pages:906–913
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.906

Preview Abstract
OBJECTIVE: This study was designed to investigate the link among attention deficit hyperactivity disorder (ADHD) in adults, novelty-seeking temperament, and the 48-base pair (bp) dopamine D4 receptor (DRD4) gene variant. METHOD: This study drew from a ...
May 2005
Brain Serotonin Transporter Distribution in Subjects With Impulsive Aggressivity: A Positron Emission Study With [11C]McN 5652
  • Pages:915–923
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.915

Preview Abstract
OBJECTIVE: The serotonin system is believed to play a role in modulating impulsivity and violence. Previous imaging studies have implicated the anterior cingulate and orbitofrontal cortex in impulsive aggression. This study evaluated regional serotonin ...
May 2005
Association of the Serotonin Transporter Gene With Smoking Behavior
  • Pages:924–930
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.924

Preview Abstract
OBJECTIVE: In an ongoing molecular genetic study of temperament, participants were genotyped to examine the association of smoking with two polymorphisms of the serotonin transporter gene (SERT): the promoter region, 5-HTTLPR, and an intronic variable-...
May 2005
Thalamic and Prefrontal FDG Uptake in Never Medicated Patients With Schizophrenia
  • Pages:931–938
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.931

Preview Abstract
OBJECTIVE: Because neuroleptic treatment may cause long-lasting changes in brain structure and function, a group of patients with schizophrenia who had never been medicated was recruited to examine regional glucose metabolic rates in the frontal-striato-...
May 2005
Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment
  • Pages:939–946
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.939

Preview Abstract
OBJECTIVE: It is widely held that there is a delayed onset of antipsychotic action and that any early effects represent nonspecific behavioral effects. Recent research has shown that antipsychotic action begins within the first week. The authors tested ...
May 2005
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
  • the Early Psychosis Global Working Group
  • Pages:947–953
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.947

Preview Abstract
OBJECTIVE: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment cornerstone during the first years of illness ...
May 2005
A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain
  • Pages:954–962
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.954

Preview Abstract
OBJECTIVE: Weight gain is commonly observed with olanzapine treatment and can increase the risk for obesity, cardiovascular disease, hypertension, and diabetes mellitus. This study examined the effectiveness of sibutramine, an approved weight loss agent, ...
May 2005
Does Memory of a Traumatic Event Increase the Risk for Posttraumatic Stress Disorder in Patients With Traumatic Brain Injury? A Prospective Study
  • Pages:963–969
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.963

Preview Abstract
OBJECTIVE: The present study examined prospectively the relationship between memory of the traumatic event and subsequent development of posttraumatic stress disorder (PTSD). More specifically, the aims of this study were to 1) investigate the possibility ...
May 2005
The Impact of Comorbid Posttraumatic Stress Disorder on Short-Term Clinical Outcome in Hospitalized Patients With Depression
  • Pages:970–976
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.970

Preview Abstract
OBJECTIVE: Posttraumatic stress disorder (PTSD) is often comorbid with other psychiatric disorders but often goes unrecognized. The effects of PTSD comorbidity are unclear, especially in patients with severe mental illness. The authors assessed short-term ...
May 2005
Relief of Expressed Suicidal Intent by ECT: A Consortium for Research in ECT Study
  • Pages:977–982
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.977

Preview Abstract
OBJECTIVE: This study assessed the incidence, severity, and course of expressed suicidal intent in depressed patients who were treated with ECT. The data are from the first phase of an ongoing, collaborative multicenter study, the overall aim of which was ...
May 2005
Functional Brain Imaging Alterations in Acne Patients Treated With Isotretinoin
  • Pages:983–991
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.983

Preview Abstract
OBJECTIVE: Although there have been case reports suggesting a relationship between treatment with the acne medication isotretinoin and the development of depression and suicide, this topic remains controversial. In order for isotretinoin to cause ...
Brief Report
May 2005
Higher Levels of Basal Serial CSF Cortisol in Combat Veterans With Posttraumatic Stress Disorder
  • Pages:992–994
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.992

Preview Abstract
OBJECTIVE: Results of basal peripheral cortisol measures in posttraumatic stress disorder (PTSD) have been variable. The authors’ goal was to measure CSF cortisol concentrations, which more accurately reflect brain glucocorticoid exposure, in subjects ...
May 2005
Childhood Trauma and Personality Disorder: Positive Correlation With Adult CSF Corticotropin-Releasing Factor Concentrations
  • Pages:995–997
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.995

Preview Abstract
OBJECTIVE: To test the hypothesis that early life trauma results in adult stress hormone alterations in individuals with personality disorders, the authors examined the relationship between history of childhood adversity and lumbar CSF corticotropin-...
May 2005
Circadian Rhythm of Salivary Cortisol in Holocaust Survivors With and Without PTSD
  • Pages:998–1000
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.998

Preview Abstract
OBJECTIVE: The authors’ goal was to determine whether cortisol circadian rhythm alterations observed in younger subjects with posttraumatic stress disorder (PTSD) are also present in geriatric trauma survivors with PTSD. METHOD: Salivary cortisol levels ...
May 2005
Posttraumatic Stress Disorder and Memory Problems After Female Genital Mutilation
  • Pages:1000–1002
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1000

Preview Abstract
OBJECTIVE: This pilot study investigated the mental health status of women after genital mutilation. Although experts have assumed that circumcised women are more prone to developing psychiatric illnesses than the general population, there has been little ...
May 2005
Alcohol and Aldehyde Dehydrogenase Polymorphisms in Men With Type I and Type II Alcoholism
  • Pages:1003–1005
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1003

Preview Abstract
OBJECTIVE: The authors examined the genetic polymorphisms of alcohol dehydrogenase 2 and 3 (ADH2 and ADH3) and aldehyde dehydrogenase (ALDH2) in patients diagnosed as having Cloninger’s type I or type II alcoholism. METHOD: Seventy-two alcoholic men and ...
May 2005
Association of Genetic Variants in Alcohol Dehydrogenase 4 With Alcohol Dependence in Brazilian Patients
  • Pages:1005–1007
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1005

Preview Abstract
OBJECTIVE: The authors evaluated the association of three functional promoter polymorphisms of the ADH4 gene with alcohol dependence. METHOD: DNA from 92 alcohol-dependent patients and 92 healthy comparison subjects was genotyped for all three ...
May 2005
Substance Abuse in First-Episode Bipolar I Disorder: Indications for Early Intervention
  • Pages:1008–1010
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1008

Preview Abstract
OBJECTIVE: This study clarified the early characteristics of substance use disorders in patients with first-episode bipolar I disorder. METHOD: The authors evaluated substance use disorders, associated factors, and clinical course, prospectively, in the ...
May 2005
Predominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin Levels
  • Pages:1010–1012
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1010

Preview Abstract
OBJECTIVE: The atypical antipsychotic risperidone significantly raises plasma prolactin levels in patients, but clozapine, olanzapine, and quetiapine do not. The differences in neuroendocrine response may be connected with the metabolism of the ...
May 2005
The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia
  • Pages:1013–1016
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1013

Preview Abstract
OBJECTIVE: The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia. METHOD: Spatial working memory performance was evaluated at baseline and after 17 and 29 weeks ...
May 2005
Familial Aggregation of Suicidal Behavior: A Family Study of Male Suicide Completers From the General Population
  • Pages:1017–1019
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1017

Preview Abstract
OBJECTIVE: This study compared suicidality in families of adult male suicide completers and community comparison subjects. METHOD: Two hundred forty-seven relatives of 25 male suicide completers and 171 relatives of 25 matched comparison subjects were ...
Letter to the Editor
May 2005
Quetiapine Discontinuation Syndrome
  • Page:1020
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1020

May 2005
Low IQ and Gasoline Huffing: The Perpetuation Cycle
  • Pages:1020-a–1021
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1020-a

May 2005
Bipolar Disorder and Niemann-Pick Disease Type C
  • Pages:1021-a–1022
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1021-a

May 2005
Suicide and Latitude in Argentina: Durkheim Upside-Down
  • Page:1022
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1022

May 2005
Dr. Dalton and Colleagues Reply
  • Pages:1024-a–1025
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1024-a

May 2005
Dr. Cassano Replies
  • Pages:1025-a–1025
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1025-a

May 2005
Sertraline for Recurrent Major Depression
  • Pages:1025-b–1026
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1025-b

May 2005
Psychiatry and General Practitioners
  • Page:1026
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1026

May 2005
Psychotropic Medication and Stroke Outcome
  • Pages:1026-a–1027
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1026-a

May 2005
Psychotropic Medication and Stroke Outcome
  • Page:1027
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1027

May 2005
Dr. Herrmann and Colleagues Reply
  • Pages:1027-a–1028
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1027-a

May 2005
Dr. Marder and Colleagues Reply
  • MT. SINAI CONFERENCE PARTICIPANTS
  • Page:1029
  • Published Online:24 January 2015

https://doi.org/10.1176/appi.ajp.162.5.1029

May 2005
Comment on Hoarding
  • Page:1031
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1031

May 2005
Dr. Saxena Replies
  • Pages:1031-a–1032
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1031-a

Book Forum: Geriatric Psychiatry
Book Forum: Posttraumatic Stress Disorder
Book Forum: Substance/Alcohol Abuse
May 2005
Handbook of Clinical Alcoholism Treatment
  • Pages:1038–1039
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1038

Book Forum: Cultural Psychiatry
May 2005
Clinician’s Guide to Cultural Psychiatry
  • Pages:1041–1042
  • Published Online:1 May 2005

https://doi.org/10.1176/ajp.162.5.1041

Correction
May 2005
Correction
  • Page:1042
  • Published Online:1 May 2005

https://doi.org/10.1176/appi.ajp.162.5.1042

May 2005
Correction
  • Pages:1042-a–1042
  • Published Online:1 May 2005

https://doi.org/10.1176/ajp.162.5.1042-a

[8]ページ先頭
©2009-2026 Movatter.jp